肠道微生物群和急性白血病:对早期诊断和新疗法的影响
Xinwei Huang1, Haibo Cai2, Yanqin Zhao3
1Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, China.
肠道微生物群通过漏肠和细菌代谢物等途径影响急性白血病 (AL) 的发展. 准肠道细菌可能为这种血液性恶性瘤提供新的诊断和治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 微生物组研究 微生物组研究
背景情况:
- 急性白血病 (AL) 是一种异质的血液性恶性瘤,在病变发生,诊断和治疗方面存在持续的挑战.
- 最近的研究强调了肠道微生物在AL进展中的重要作用.
研究的目的:
- 总结肠道微生物群对急性白血病产生有所贡献的机制.
- 探索肠道微生物群作为AL早期诊断生物标志物的潜力.
- 讨论未来针对AL预防的肠道微生物群的治疗策略.
主要方法:
- 文献综述和关于肠道微生物群和急性白血病的研究综合.
- 分析涉及微生物群驱动的AL发展的关键途径.
- 讨论诊断和治疗方面的影响.
主要成果:
- 肠道微生物群通过包括漏肠,细菌失生症,分子模式和代谢物在内的机制影响AL的发展.
- 肠道微生物群组成的变化与AL病变发生有关.
- 肠道微生物群作为早期发现AL的生物标志物具有潜力.
结论:
- 肠道微生物群在急性白血病的发展和进展中起着至关重要的作用.
- 准肠道微生物组为早期AL诊断和新的治疗干预提供了有希望的途径.
更多相关视频
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
